Mark A. King

Phase II Trial of Sorafenib in Metastatic Thyroid Cancer

PURPOSEnBased on the pivotal role of Ras-Raf-MAP-ERK signaling and vascular endothelial growth factor (VEGF) in papillary thyroid cancer (PTC), we conducted a phase II clinical trial of sorafenib targeting RAF and VEGF receptor kinases in PTC.nnnPATIENTS AND METHODSnThe primary end point was the objective response rate. Secondary end points included response correlation with serum thyroglobulin (Tg); functional imaging; tumor genotype; and signaling inhibition in tumor biopsies. Using a Simon minimax two-stage design, 16 or 25 chemotherapy-naïve metastatic PTC patients were to be enrolled in arm A (accessible tumor for biopsy). Arm B patients had other subtypes of thyroid carcinoma or prior chemotherapy, and did not require tumor biopsies. Patients received 400 mg orally twice per day of sorafenib. Response was assessed every 2 months using RECIST (Response Evaluation Criteria in Solid Tumors).nnnRESULTSnOf 41 PTC patients, six patients had a partial response (PR; 15%; 95% CI, 6 to 29) and 23 patients (56%; 95% CI, 40 to 72) had stable disease longer than 6 months. Median duration of PR was 7.5 months (range, 6 to 14). Median progression-free survival was 15 months (95% CI, 10 to 27.5). In 14 (78%) of 18 Tg-assessable PTC patients, Tg declined more than 25%. Common grade 3 adverse events included hand-foot skin reaction, musculoskeletal pain, and fatigue. BRAF mutation was detected in 17 (77%) of 22 PTCs analyzed. Four of 10 paired tumor biopsies from PTC patients showed a reduction in levels of vascular endothelial growth factor receptor phosphorylation, ERK phosphorylation, and in VEGF expression during sorafenib therapy. No PRs were noted among non-PTC patients.nnnCONCLUSIONnSorafenib is reasonably well-tolerated therapy with clinical and biologic antitumor activity in metastatic PTC.

Increased Susceptibility to Pulmonary Emphysema among HIV-Seropositive Smokers

Several reports (1-3) have suggested that before recognized AIDS-related respiratory complications develop, some HIV-seropositive persons may develop an accelerated form of lung injury that has physiologic features or findings on computed tomography of the chest that are consistent with pulmonary emphysema. Emphysema, defined as enlargement of the terminal air spaces and destruction of the alveolar walls (4), is uniquely characterized by disappearance of lung tissue (4). Insight into the cellular mechanisms critical to pathogenesis of this condition in humans has been limited by the lengthy course over which the disease develops and by the fact that only a minority of smokers develops significant disease (5). The possibility that HIV-seropositive persons may have a greater risk for developing accelerated lung destruction may have broad biological relevance regarding emphysema pathogenesis. With this in mind, we sought to extend previous anecdotal studies and attempted to prospectively characterize a group of HIV-infected persons exhibiting evidence of emphysema-like destructive lung disease. Methods The study sample consisted of 114 consecutive HIV-seropositive persons who underwent high-resolution computed tomography of the chest (1994 through 1997). This group was a sample of a larger cohort of 321 HIV-seropositive persons who had undergone a detailed assessment of respiratory symptoms and pulmonary function. Most participants were from Columbus, Ohio, and were recruited through advertisements, by word of mouth, and by the Ohio State University Medical Center AIDS-Clinical Trials Unit. Less than 10% of the participants were receiving protease inhibitors at the time of this study. Persons with a history of Pneumocystis carinii pneumonia and other pulmonary complications of AIDS were excluded. Controls consisted of 44 HIV - seronegative volunteers matched for age, sex, and smoking history; they were recruited from the general population by advertisements. All participants completed a modified American Thoracic Society Questionnaire (6) for symptoms, smoking history, drug use, history of pneumonia, and medications. Nonsmokers were identified as having a history of cumulative cigarette smoking of 1 pack-year or less. Pulmonary function studies were performed according to American Thoracic Society standards. The study was approved by the Ohio State University human subjects review board. Informed consent was obtained from all participants. Computed tomography was performed with a GE 9800 CT scanner (GE Medical Systems, Milwaukee, Wisconsin) or a Picker PQ 2000 CT scanner (Picker International, Solon, Ohio) with 1.5-mm collimation at 10-mm intervals through the chest. Scans were obtained at total lung capacity in the supine position. Images were reconstructed by using the high spatial frequency algorithm and were photographed at a lung window width of 1500 Hounsfield units (brightness level, 700 Hounsfield units). Emphysema was considered present if the scans showed evidence of bullae, thin-walled cystic spaces, or abnormal decreases in attenuation, accompanied by vascular disruption. Emphysema severity was estimated by assigning an emphysema score (0 to 10) for each lobe according to the percentage of the lobe that was affected. The lingula was considered a separate lobe. The total score represented the sum for all lobes. Scans were interpreted by two experienced chest radiologists, who were blinded to the patients HIV status and physiologic data. Participants were considered to have clear evidence of at least early emphysema if 1) the computed tomography emphysema score was 6 or higher [for example, 25% of two lobes involved with emphysema] or 2) pulmonary function tests demonstrated a total lung capacity greater than 120% of the predicted value, a diffusing capacity less than 60% of predicted, and computed tomographic evidence of emphysema in more than two lobes. Bronchoalveolar lavage and differential cell counts were performed according to standard techniques (7) on consenting participants. This included 46 HIV-seropositive smokers and 14 control smokers. A sample containing more than 1 000 000 cells was analyzed by a fluorescence-activated cell sorter for T-lymphocyte subtyping. An experienced microbiologist, who was blinded to HIV status, examined all lavage samples for the presence of fungi, acid-fast bacilli, P. carinii, and bacteria. Statistical analyses were performed by using the SAS JMP package (8). Analysis of variance was used to compare groups, and post hoc analysis was performed by using the Dunnett procedure (8). The Pearson chi-square test was used for equality of proportions; exact P values were calculated for small samples (9). Results With the exception of a lower CD4 count and diffusing capacity in the HIV-seropositive group, the two study groups had similar baseline characteristics (Table). Of note, 25% of the HIV-seropositive group had a history of oral thrush; however, other HIV-related opportunistic infections were rarely reported (<2%). The percentage of HIV-seropositive persons who reported any use of intravenous drugs was low (approximately 10%), and no significant differences in the use of intravenous drugs, crack cocaine, or marijuana were found between the HIV-seropositive group and the control group. Table. Clinical and Demographic Characteristics of the Study Groups Clinical variables did not significantly differ between the HIV-seropositive group of this study and the 321 persons in the overall HIV cohort (Table). For example, the median age of the overall cohort was 33 years (range, 20 to 66 years), the median CD4 count was 348 cells/mm3 (range, 0 to 1188 cells/mm3), and the median diffusing capacity was 83.7% of predicted (range, 38.8% to 153%). Sixty-three percent of the overall cohort smoked cigarettes. Emphysema was identified in 17 of 114 HIV-seropositive participants compared with 1 of 44 HIV-seronegative controls (P=0.025). Only one HIV-seronegative participant had a computed tomography emphysema score as high as 6, whereas 14 HIV-seropositive participants had scores between 6 and 23. The mean (SE) emphysema score for the HIV-seropositive group with emphysema was 10.5 1.7, the mean total lung capacity was 110% 6.9% of predicted, and the diffusing capacity was 60.1% 11.3% of predicted. Of note, persons with emphysema had only mild airflow obstruction (ratio of FEV1 to FVC, 69.2% 9.4%), which may relate to a higher than expected number of persons (approximately 30%) demonstrating subpleural or peripheral lesions (10). The Figure shows examples of precocious emphysema in HIV-seropositive persons, with accompanying emphysema scores. Figure. High-resolution computed tomographic scans of the chest.A. arrows B. Because a relatively high proportion of cigarette smokers appeared to be susceptible to early destructive changes, we specifically studied the role of smoking history. Thirty-seven percent (14 of 38) of HIV-seropositive smokers with a smoking history of 12 pack-years or more met criteria for emphysema, compared with 0% (0 of 14) HIV-seronegative controls (P=0.011). Furthermore, 46% (11 of 24) of HIV-seropositive participants with a smoking history of 25 pack-years or more met criteria for emphysema, compared with 0% (0 of 10) in the HIV-seronegative controls (P=0.013). Next, using current pack-year of cigarette smoking as a covariate, we compared lung-cell populations among three groups of smokers: HIV-seronegative smokers (n=14), HIV-seropositive smokers without emphysema (n=34), and HIV-seropositive smokers with emphysema (n=12). The numbers of alveolar macrophages and neutrophils in the lavage fluid were similar among the three groups. Although the two HIV-seropositive groups were found to have threefold more lymphocytes than the uninfected controls, no significant difference in lymphocyte numbers were noted between HIV-seropositive persons with and those without emphysema. However, when lymphocyte subtypes were examined, HIV-seropositive persons with emphysema were found to have the highest percentage of lavage lymphocytes bearing the cytotoxic phenotype; the mean (SE) value in this group was 58% 4.6%, compared with 46.6% 2.3% in HIV-seropositive smokers without emphysema (P<0.05) and 32.2% 4.6% in HIV-seronegative smokers (P<0.01). Of note, no pathogens were observed in microbiological stains of lavage fluid from study participants. Discussion This prospective study demonstrates the development of an accelerated form of pulmonary emphysema in a stable HIV-seropositive outpatient sample. Furthermore, the results suggest that the lesion is related to a heightened susceptibility to cigarette smoke. We hypothesize that HIV infection or secondary inflammatory abnormalities directly accelerate the process of smoking-induced parenchymal lung destruction. The cellular mechanisms predisposing HIV-seropositive smokers to emphysema are unclear. However, immunologic aspects of HIV disease may be relevant to understanding emphysema pathogenesis in the general population. Of particular interest are the many bronchoalveolar lavage and lung pathology studies that have demonstrated increased numbers of cytotoxic lymphocytes in the lungs of HIV-seropositive persons (11-13). Although prevailing theories for emphysema have focused on smoking-induced production of proteolytic enzymes by neutrophils and macrophages (4, 5), recent morphometric analyses of lung biopsy sections from non-HIV-infected smokers have demonstrated a high correlation between lung lymphocytes and the presence of emphysema (14, 15). Furthermore, experimental evidence suggests that viral activation of cytotoxic lymphocytes may contribute to parenchymal lung destruction (16). Another potential mechanism recently hypothesized is that latent viral infections may be an important cofactor in the development of chronic obstructive pulmonary disease (17). Adenoviral proteins, latently expressed in host epithelial cells, a

A pilot test of a combined tobacco dependence treatment and lung cancer screening program.

Lung cancer screening with computed tomography has demonstrated a significant reduction in mortality. While these findings are important for the lung cancer research field, the most important risk factor for lung cancer, i.e. smoking, should not be ignored. We performed a pilot study to examine the feasibility of delivering a program that included both tobacco dependence treatment and lung cancer screening. The objectives of this study were to: (1) estimate the proportion of smokers who complied with a 12-week treatment protocol that included both tobacco dependence treatment and lung cancer screening, (2) obtain preliminary estimates of abstinence and quit attempts at 4 and 6 months, and (3) obtain preliminary estimates of the cognitive social health information processing (C-SHIP) constructs and how they change following the intervention. In this randomized pilot study, 18 volunteers completed a 12-week protocol: half received the tobacco dependence treatment program before a CT scan (BCT) and the other received the CT scan first, followed by the treatment program (ACT). The treatment protocol included both nurse-delivered telephone counseling and either nicotine replacement therapy or varenicline. Only one person did not complete all follow-up evaluations. At 4 months post enrollment, the carbon monoxide confirmed quit rates were 33.3% in the BCT arm and 22.2% in the ACT arm (27.8% overall), and all but one had made a 24-h attempt to quit. At 6 months the confirmed abstinence decreased to 22.1% in the BCT arm and 11.1% in the ACT arm (16.7% overall), and 72.2% of participants had made a 24-h quit attempt. These preliminary results suggest that it might be better to deliver treatment before the screening test. Future randomized trials with a larger sample size are needed to confirm these findings.

Analysis of frequency of pulmonary atelectasis in patients undergoing pectoralis major musculocutaneous flap reconstruction

The incidence of pulmonary atelectasis following head and neck surgery is not well reported. This study retrospectively evaluated the incidence of pulmonary atelectasis in 161 head and neck cancer patients, with 152 being evaluable. There were 90 patients evaluated following pectoralis musculocutaneous flap reconstruction with their effective flap size and 71 nonflap patients as a control group. Clinical findings were correlated to radiographic scores. Of pectoralis musculocutaneous flap patients screened for preexisting pulmonary disease (PEPD), nine of 45 (20%) demonstrated pulmonary atelectasis in the first 24 hours compared with 10 of 39 or 25.6% nonflap controls. Major pulmonary atelectasis was not found in the pectoralis musculocutaneous flap patients by scoring criteria, and in only one of 39 (2.6%) nonflap patients. In flaps larger than 40 cm2, the incidence was eight of 37 (21.6%), with no major pulmonary atelectasis noted. Only one of nine (11.1%) patients with radiographic pulmonary atelectasis exhibited clinical symptoms (three of 10 or 30% control). In patients with PEPD and pectoralis musculocutaneous flaps, 22 of 45 (48.9%) had evidence of pulmonary atelectasis in contrast to 13 of 32 or 40.6% controls. There were two of 45 (4.4%) who had major pulmonary atelectasis with zero of 32 in the nonflap group. For flaps larger than 40 cm2, the incidence was 19 of 39 (48.7%) with two of 39 (5.1%) scored as major pulmonary atelectasis. The clinical correlation for this group and the major pulmonary atelectasis group was each approximately 50% compared to 15.4% for nonflap patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Risk Factors Associated With Quantitative Evidence of Lung Emphysema and Fibrosis in an HIV-Infected Cohort.

Introduction:The disease spectrum for HIV-infected individuals has shifted toward comorbid non-AIDS conditions including chronic lung disease, but quantitative image analysis of lung disease has not been performed. Objectives:To quantify the prevalence of structural changes of the lung indicating emphysema or fibrosis on radiographic examination. Methods:A cross-sectional analysis of 510 HIV-infected participants in the multicenter Lung-HIV study was performed. Data collected included demographics, biological markers of HIV, pulmonary function testing, and chest computed tomographic examinations. Emphysema and fibrosis-like changes were quantified on computed tomographic images based on threshold approaches. Results:In our cohort, 69% was on antiretroviral therapy, 13% had a current CD4 cell count less than 200 cells per microliter, 39% had an HIV viral load greater than 500 copies per milliliter, and 25% had at least a trace level of emphysema (defined as >2.5% of voxels <−950HU). Trace emphysema was significantly correlated with age, smoking, and pulmonary function. Neither current CD4 cell count nor HIV viral load was significantly correlated with emphysema. Fibrosis-like changes were detected in 29% of the participants and were significantly correlated with HIV viral load (Pearson correlation coefficient = 0.210; P < 0.05); current CD4 cell count was not associated with fibrosis. In multivariable analyses including age, race, and smoking status, HIV viral load remained significantly correlated with fibrosis-like changes (coefficient = 0.107; P = 0.03). Conclusions:A higher HIV viral load was significantly associated with fibrosis-like changes, possibly indicating early interstitial lung disease, but emphysematous changes were not related to current CD4 cell count or HIV viral load.

Quantitative computerized two-point correlation analysis of lung CT scans correlates with pulmonary function in pulmonary sarcoidosis.

BACKGROUNDnChest CT scans are commonly used to clinically assess disease severity in patients presenting with pulmonary sarcoidosis. Despite their ability to reliably detect subtle changes in lung disease, the utility of chest CT scans for guiding therapy is limited by the fact that image interpretation by radiologists is qualitative and highly variable. We sought to create a computerized CT image analysis tool that would provide quantitative and clinically relevant information.nnnMETHODSnWe established that a two-point correlation analysis approach reduced the background signal attendant to normal lung structures, such as blood vessels, airways, and lymphatics while highlighting diseased tissue. This approach was applied to multiple lung fields to generate an overall lung texture score (LTS) representing the quantity of diseased lung parenchyma. Using deidentified lung CT scan and pulmonary function test (PFT) data from The Ohio State University Medical Centers Information Warehouse, we analyzed 71 consecutive CT scans from patients with sarcoidosis for whom simultaneous matching PFTs were available to determine whether the LTS correlated with standard PFT results.nnnRESULTSnWe found a high correlation between LTS and FVC, total lung capacity, and diffusing capacity of the lung for carbon monoxide (P < .0001 for all comparisons). Moreover, LTS was equivalent to PFTs for the detection of active lung disease. The image analysis protocol was conducted quickly (< 1 min per study) on a standard laptop computer connected to a publicly available National Institutes of Health ImageJ toolkit.nnnCONCLUSIONSnThe two-point image analysis tool is highly practical and appears to reliably assess lung disease severity. We predict that this tool will be useful for clinical and research applications.

Gender Differences in Pulmonary Function, Respiratory Symptoms, and Macrophage Proteomics among HIV-Infected Smokers

Background. HIV-infected subjects have an increased incidence of pulmonary emphysema. There are known gender differences in COPD phenotypic expression and diagnosis, but this is not well characterized in lung disease related to HIV. We analyzed a group at risk for the development of COPD (HIV-infected smokers) to determine gender differences in pulmonary symptoms, pulmonary function tests, and HRCT appearances. Methods. This was a cross-sectional, baseline analysis of a prospective study performed between 2006 and 2010. We performed symptomatic, pulmonary function, and computed tomography assessments in 243 HIV-infected smokers. In a subset bronchoalveolar lavage was performed with proteomic analysis of their alveolar macrophages. Results. The majority of the participants were male 213 (87.6%). There was significantly higher percentage of cough and phlegm production in males. There was also a lower FEV1 and a higher RV in males than females. Proteomic analysis revealed 29 proteins with at least a 2-fold higher expression in males and 13 identified proteins that were higher in females. Conclusions. In this group of HIV-infected smokers, airway symptoms and pulmonary function test abnormalities were higher in men than women. These gender differences may be due to differential expression of certain proteins in this group.

MR diagnosis of lymphangioleiomyomatosis: Visibility of pulmonary cysts on spin-echo images

The signs and symptoms of pulmonary lymphangioleiomyomatosis are nonspecific, but the radiographic findings, particularly those on computed tomographic (CT) scans, often suggest the diagnosis. Although evaluation of the lungs on magnetic resonance (MR) scans is limited, MR findings in some diffuse lung diseases have been described. This report illustrates a case of lymphangioleiomyomatosis in which the diagnosis was suggested by the appearance of the lungs on spin-echo MR images.